Enrica
Bortolamiol
a,
Francesco
Fama
a,
Ziyun
Zhang
b,
Nicola
Demitri
c,
Luigi
Cavallo
b,
Isabella
Caligiuri
d,
Flavio
Rizzolio
*ad,
Thomas
Scattolin
*e and
Fabiano
Visentin
*a
aDipartimento di Scienze Molecolari e Nanosistemi, Università Ca’ Foscari, Campus Scientifico Via Torino 155, 30174 Venezia-Mestre, Italy. E-mail: fvise@unive.it
bDepartment KAUST Catalysis Centre, KCC, King Abdullah University of Science and Technology, Thuwal-23955-6900, Saudi Arabia
cElettra – Sincrotrone Trieste, S.S. 14 Km 163.5 in Area Science Park, 34149 Basovizza, Trieste, Italy
dPathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS, via Franco Gallini 2, 33081, Aviano, Italy. E-mail: flavio.rizzolio@unive.it
eDipartimento di Scienze Chimiche, Università degli Studi di Padova, via Marzolo 1, 35131 Padova, Italy. E-mail: thomas.scattolin@unipd.it
First published on 28th June 2022
The reactivity of palladium(II) indenyl derivatives and their applications are topics relatively less studied, though in recent times these compounds have been used as pre-catalysts able to promote challenging cross-coupling processes. Herein, we propose the first systematic study concerning the nucleophilic attack on the palladium(II) coordinated indenyl fragment and, for this purpose, we have prepared a library of new Pd-indenyl complexes bearing mono- or bidentate phosphines as spectator ligands, developing specific synthetic strategies. All novel compounds are thoroughly characterized, highlighting that the indenyl ligand presents always a hapticity intermediate between η3 and η5. Secondary amines have been chosen as nucleophiles for the present study and indenyl amination has been monitored by UV-Vis and NMR spectroscopies, deriving a second order rate law, with dependence on both complex and amine concentrations. The rate-determining step of the process is the initial attack of the amine to the coordinated indenyl fragment, and this conclusion has been supported also by DFT calculations. The determination of second order rate constants has allowed us to assess the impact of the phosphine ligands on the kinetics of the process and identify the steric and electronic descriptors most suitable for predicting the reactivity of these systems. Finally, in vitro tests have proven that these organometallic compounds promote antiproliferative activity towards ovarian cancer cells better than cisplatin and possibly by adopting a different mechanism of action.
Scheme 1 Significant examples of Pd(II)- and Pd(I)-indenyl complexes.4–7 |
Remarkably, all complexes are characterized by a formal electron count of 16 and somehow, this feature ends up determining the hapticity of the indenyl ligand.
However, it should be stressed that the η3-binding mode of the complexes reported in Scheme 1 has a certain percentage of η5-character, which can be quantified by well-defined structural2,8 and spectroscopic9 parameters. Generally speaking, an increase of the degree of pentahapto coordination mode is associated with approaching to the planarity of the five-membered ring with its five carbons tending to have very similar distances from the metal centre.
Seminal works of the Zargarian group have shown the capability of some Pd(II)-indenyl derivatives to catalyse a wide range of organic processes such as isomerization, oligomerization and polymerization of olefins and Mizoroki–Heck coupling.3,10,11 More recently, Hazari and Nolan have developed a series of precatalysts of the type [PdCl(1-tBu-indenyl)(L)] (with L = NHC or Buchwald-type phosphine) able to promote a number of challenging cross-coupling processes such as α-arylation of methyl ketones, and Suzuki–Miyaura and Buchwald–Hartwig reactions with deactivated substrates.12 The key to success of these derivatives stems from the presence of the 1-tBu-indenyl scaffold which facilitates the selective formation of active Pd(0)-monoligated species disfavouring the production of inactive Pd(I) dimers.
The literature provides much less information on cationic palladium-indenyl species of the type [Pd(indenyl)(L2)]+,11,13 and above all no specific studies of their reactivity can be found. This is particularly striking in relation to the large number of publications dealing with their η3-allyl counterparts. For example, it is well-known that these derivatives are key-intermediates in the Tsuji–Trost catalytic cycle during which they are subjected to nucleophilic attack on the allyl fragment by many suitable substrates resulting in allyl substituted products.14 In the past, our research group has studied the kinetics and reaction mechanisms of palladium-allyl amination, assessing the influence of spectator ligands, allyl substituents, the type of amine and solvent.15
In this work we aim at filling the knowledge gap concerning the nucleophilic attack on palladium(II) coordinated indenyl. The choice of an amine as a nucleophilic agent allows us to take advantage of the information obtained from our previous studies on allyl derivatives and, at the same time, compare the behaviour of these two organometallic systems. In this regard, we have opted to prepare an array of Pd(II)-indenyl complexes equipped with aryl(hetero)phosphines as supporting ligands, since they have been shown to be efficient for promoting allyl amination and also, as is well-known, their steric/electronic features can be easily fine-tuned.
Finally, encouraged by the recent results obtained on the antiproliferative activity of cationic palladium-η3-allyl derivatives towards cancer cells,17 we wanted to see if these promising properties could also be extended to these novel Pd(II)-indenyl derivatives.
Further information about the palladium-indenyl interaction can be deduced by the chemical shift of junction carbons C3a and C7a. As a matter of fact, according to the Baker and Marder empirical protocol,9 the magnitude of Δδ (13C) = δ (C3a/7a of M-Ind) − δ (C3a/7a of Na+Ind−) is correlated with the hapticity of the indenyl fragment in solution. In this series of compounds Δδ (13C) is always between +2.8 and +6.2 ppm, (Table S7 in the ESI†) basically indicating intermediate hapticity between η3 and η5.
Of course, it is possible to operate without isolating the neutral complex [PdCl(indenyl)(PAr3)], starting directly from [Pd(μ-Cl)(indenyl)]2 and adding in succession one equivalent of phosphine, the sodium salt in methanol solution and finally the second equivalent of phosphine. With this synthetic protocol we were able to isolate all the final products, except for the complex bearing two tris(4-trifluoromethylphenyl)phosphine, which decomposes readily during the synthesis.
The only peak exhibited by the 31P{1H} NMR spectra of the new complexes [Pd(indenyl)(PAr3)2]ClO4 is always localised at chemical shifts slightly lower than that of the corresponding neutral species [PdCl(indenyl)(PAr3)], (except for the compound coordinating two tri(2-furyl)phosphines). Moreover, the higher symmetry of these complexes greatly simplifies 1H and 13C{1H} NMR spectra, where the coincident H1–H3 and C1–C3 resonate at 5.5 and 96 ppm, respectively. From the position of C3a/7a, it is possible to obtain Δδ (13C) values which, being always very close to zero, (see Table S7 in the ESI†) indicate that the indenyl ligand exhibits a hapticity intermediate between η3 and η5 also in these cationic species. This bonding motif is further confirmed by the structure obtained by single crystal X-ray diffraction of complex 3b (Fig. 1), from which it was possible to determine the structural parameters ΔM–C,18 hinges and fold angles (HA19 and FA20). Their values (0.298 Å, 13.24° and 11.65°, respectively) are consistent with an intermediate coordination between η3 and η5 of the indenyl fragment.2
Fig. 1 X-ray molecular structure of 3b, showing thermal displacement ellipsoids at the 50% probability level with the hydrogen atoms, counterion and solvent molecules omitted for clarity. |
Finally, the presence of two intense bands at about 1080 and 620 cm−1 in the IR spectra, attributable to νClO4 and δClO4 respectively, indirectly certifies the cationic nature of the synthesized complexes.
A special case is represented by XPhos (2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) which interacts with the Pd-indenyl fragment in a different way from the other monodentate phosphines investigated so far. This is largely due to its peculiar structure and high steric hindrance.21
Indeed, using the same synthetic protocol described above the coordination of only one XPhos molecule can be obtained (Scheme 4). The definitive structure of the final cationic complex [Pd(indenyl)(XPhos)]ClO4 (3h) was determined by single crystal X-ray analysis and a view of that is shown in Fig. 2.
Fig. 2 X-ray molecular structure of 3h, showing thermal displacement ellipsoids at the 50% probability level with the hydrogen atoms, counterion and solvent molecules omitted for clarity. |
From this study it emerges that XPhos is anchored to the metal centre with the phosphorus donor atom and via a η2-coordination of non-phosphine containing an aryl-ring as witnessed by Pd–C19_3 and Pd–C20_3 distances (2.367 and 2.490 Å, respectively). This binding motif is quite unusual but has already been observed in other palladium(II) complexes.22
NMR studies confirm that the structure in solution is the same as that in the solid state. As a matter of fact, the integration of the signals in the 1H NMR spectrum proves that the ratio between the indenyl fragment and coordinated phosphine is 1:1. Moreover, seven and nine different signals attributable to indenyl fragment spectra are traceable in 1H and 13C{1H} NMR, respectively, as a direct consequence of the described coordination mode of XPhos. Finally, the only signal present in 31P{1H}NMR spectra resonates at a chemical shift significantly higher than that in free XPhos (Δδ = 65 ppm), certifying the coordination of the phosphine to a more electron-poor metal centre than those of the bis-phosphine-cationic complexes described above.
As usual, NMR analysis helps us to confirm the identity of the isolated compounds. As a natural consequence of the coordination of a symmetric chelate ligand on the metal centre, all 31P{1H} NMR spectra are characterised by the presence of a single peak resonating at chemical shifts significantly higher than that in the uncoordinated diphosphine. Among the signals detectable in 1H and 13C{1H} NMR spectra, it is possible to easily distinguish those belonging to the indenyl moiety, among which H1/H3 and C1/C3 can be found at 5.3–6.3 and 90–95 ppm, respectively. Also, in these derivatives the hapticity of the indenyl ligand is intermediate between η3 and η5, as inferred from the small values of Δδ(13C) and ΔM–C, and HA and FA parameters (see Tables S2–7 in the ESI†). The latter were derived from the X-ray structures of complexes 4, 5 and 6 (Fig. 3).
Finally, the single peak present in 19F{1H} NMR spectra, detectable at a typical resonance frequency of −78 ppm, certifies the presence of the triflate counterion.
Scheme 6 Reaction of indenyl amination with piperidine ([complex] = 5 × 10−5–1 × 10−4 mol dm−3, [dimetylfumarate] = 1.5 × 10−4–3 × 10−4 mol dm−3, [piperidine] ≥ 10[complex]; in CHCl3, T = 298 K). |
The reaction monitoring by 1H NMR spectroscopy shows that the initially formed 1-(1H-inden-1-yl)piperidine slowly isomerizes to the more thermodynamically stable 1-(1H-inden-3-yl)piperidine (using DFT calculations the difference amounts to 9.1 kcal mol−1). This process, which is possibly catalysed by basic conditions24 (excess of piperidine), proceeds, in most cases, much more slowly than the indenyl amination of palladium complexes. It is important to stress that the nature of the final organic product 1-(1H-inden-3-yl)piperidine is attested as well as by the presence of its expected signals in the 1H NMR spectra (in good agreement with those of the simulated spectrum) and by GC-MS analysis of the final reaction mixture (Fig. S96 in the ESI†). The identity of the final complexes [Pd(η2-dmfu)(PAr3)2] and [Pd(η2-dmfu)(P–P)] can be unambiguously ascertained by comparing the signals present in the final reaction mixture with those of the 1H and 31P{1H} NMR spectra of these Pd(0) derivatives obtained independently in the past by another synthetic route (e.g. reacting [Pd2(dba)3]·CHCl3 with dmfu and the respective phosphine).25
These preliminary studies also provide us with general information about the rate of the process. Under the experimental conditions used (298 K, CDCl3, [Pd-indenyl complex] = 1 × 10−2 mol dm−3 and [piperidine] = 5 × 10−2 mol dm−3), all reactions are completed in a few minutes, with the only exceptions represented by complexes [Pd(DPPE)(indenyl)]OTf, [Pd(DPPP)(indenyl)]OTf and [Pd(DPPBz)(indenyl)]OTf which need a few hours to reach completion. Excluding the last cases, for which we have reserved a separate treatment (vide infra), a general kinetic study has been carried out taking advantage of UV-Vis spectroscopy. As matter of fact, all our Pd-indenyl derivatives are strongly coloured (deep-orange) and show a strong absorption band at around 400 nm that gradually decreases during the reaction. The presence of an isosbestic point, localized in all cases at around 380 nm, suggests the absence of intermediate species at significant concentrations.
For quantitative kinetic measurements, the course of reactions of CHCl3 solutions of Pd-indenyl complexes (1 × 10−4 or 5 × 10−5 mol dm−3) in the presence of dimethyl fumarate (3 × 10−4 or 1.5 × 10−4 mol dm−3), upon addition of variable aliquots of a large excess of piperidine, was monitored at a wavelength of 400 nm. Under such pseudo-first order conditions the reaction proceeded smoothly to completion in a few minutes, and over this period of time, as proved by previous NMR studies, the isomerization from 1-(1H-inden-1-yl)piperidine to 1-(1H-inden-3-yl)piperidine can be neglected.
The conversion of Pd-indenyl complexes to the final Pd(0) derivatives appears to obey the customary mono-exponential absorbance (At) vs. time (t) relationship (Fig. 4):
At = A∞ + (A0 − A∞)exp(−kobst) |
The pseudo first order rate constants kobs were derived by nonlinear regression of absorbance At data to time.
For all reactions examined, kobs values fit the simple linear relationship (inset Fig. 4):
kobs = k2 [piperidine] |
Therefore, it can be concluded that the kinetic law governing this process is of the second order, with dependence on both the Pd-indenyl complex and amine concentrations:
rate = k2 [complex][piperidine] |
This result is in accordance with a mechanism where the initial bimolecular attack of amine to the coordinated indenyl fragment represents the rate-determining step of the process, as already observed for the corresponding Pd-allyl complexes (Scheme 6).
The values of second-order constants relative to complexes bearing monodentate phosphines are listed in Table 1.
Compound | k 2 (mol−1 dm3 s−1) |
---|---|
3a | 55.5 ± 1.9 |
3b | 420 ± 20 |
3c | 250 ± 20 |
3e | 6.4 ± 0.1 |
3f | 13.3 ± 0.4 |
3g | 410 ± 10 |
3h | 13.1 ± 0.7 |
In the light of these data, we can propose the following observations:
(a) Considering the four complexes equipped with monodentate aryl-phosphines 3a–c and 3e, the influence of the different substituents in the para-position is apparent, with the k2 values increasing with an increase in the electron-withdrawing nature of the substituents. This observation is in full agreement with the proposed mechanism whereby a more electron-poor metal centre makes the coordinated indenyl fragment more susceptible to nucleophilic attack. This effect can be somewhat systematized recurring to the Hammett equation: fitting logk2 values vs. tabulated para-substituent σ constants, we can obtain the value of the reaction constant ρ amounting to 3.7 ± 0.7 (Fig. S95 in the ESI†).
(b) The particularly high reactivity of [Pd(indenyl)(P(2-furyl)3)2]ClO4 (3g) is also due to the high electron-withdrawing nature of hetero-aryl phosphines.
(c) Intriguingly, the complex [Pd(indenyl)(P(Ph)2(2-py))2]ClO4 (3f) shows lower reactivity than the very structurally similar [Pd(indenyl)(PPh3)2]ClO4 (3a) as opposed to what would be expected considering that the replacement of a phenyl with a more electron withdrawing pyridyl ring should have an activating effect. We can therefore assume that there is some form of stabilization of the starting complex or destabilization of the transition state of the rate-determining step, promoted by pyridyl-nitrogen.
Limited to complex [Pd(indenyl)(PPh3)2]ClO4 (3a), we have also determined the rate constants k2, when diethylamine and morpholine are used as nucleophiles. The choice of these two different amines was made to better assess the weight of steric and electronic effects on this kind of reaction. As a matter of fact, morpholine has the same steric hindrance as piperidine but less basicity, whereas diethylamine has the same basicity but is more sterically encumbered. Consistently, both resulted in a k2 value lower than that of piperidine (23 ± 1 and 4.9 ± 0.1 vs. 56 ± 2, respectively), but the decrease of one order of magnitude recorded for diethylamine seems to indicate that the steric factor plays a more important role than the electronic one.
The complex [Pd(indenyl)(XPhos)]ClO4 (3h), which differs from those examined so far for the presence of an only coordinated phosphine, reacts with piperidine more slowly than expected considering that the indenyl fragment is bound to a more electron-poor metal centre. This fact is possibly due to more steric congestion around the indenyl ligand (see Fig. 2).
For what concerns the complexes equipped with bidentate phosphines, only two of the prepared compounds (6 and 8) are reactive enough to determine the relative k2 rate constant at the concentrations adopted for spectrophotometric studies. For the remaining three complexes (4, 5, and 7), the reactions have been monitored by 31P{1H} NMR spectroscopy, which allows working at higher concentrations thus making the process faster. A series of preliminary tests have helped us to define the best conditions to carry out the experiments (see the Experimental section). The two equations used to determine the k2 rate constants are in this case:
d[complex]/dt = k2[complex][piperidine] |
[piperidine] = [piperidine]0–2[complex] |
Compound | k 2 (mol−1 dm3 s−1) | Bite angle (°) |
---|---|---|
4 | (4.0 ± 0.2) × 10−2 | 86 |
5 | (7.1 ± 0.3) × 10−2 | 91 |
6 | 1.81 ± 0.9 | 99 |
7 | (2.08 ± 0.06) × 10−2 | 83 |
8 | 8.50 ± 0.4 | 104 |
9 | 0.607 ± 0.002 | 86 |
It may finally be interesting to compare the reactivity of Pd-indenyl with that of the Pd-allyl fragment. To this end, we have chosen the two complexes coordinating 1,2 bis(diphenylphosphine)ethane [Pd(DPPE)(indenyl)]OTf (4) and [Pd(DPPE)(η3-allyl)]OTf (9). The latter has been synthesized with the same method of its indenyl congener, starting from the dimeric precursor [Pd(μ-Cl)(η3-allyl)]2. The first preliminary test carried out in the NMR tube has shown the higher reactivity of the Pd-allyl complex 9 with piperidine compared to 4, completing the reaction after a few minutes. A more detailed UV-Vis spectrophotometric study has allowed determining the k2 rate constant relative to this substrate that, amounting to 0.607 ± 0.002 mol−1 dm3 s−1, is about one order of magnitude higher than that of the corresponding indenyl derivative 4. This effect can be attributed to the partial η5-character adopted by an indenyl fragment in this type of complex, which strengthens its bond with the palladium centre, and disadvantages the nucleophilic attack.
With these data in hand, DFT calculations were performed. X-ray molecular structures (when available) were used as a starting point for geometry optimizations.
Initial efforts were made to compare the trend in the rate constants with the energy barriers of the rate-determining step. To this end we selected the two most active systems, 3b and 3g, and the two of the least active ones, 3a and 3f. As shown in Fig. 5, the calculated energy barriers for the initial nucleophilic attack of piperdine to the indenyl fragment are 13.0 and 12.7 kcal mol−1 for 3b and 3g (high reactivity) and 13.8 and 15.4 for 3a and 3f (lower reactivity), respectively. This is in agreement with the experimentally observed trend of rate constants.
Fig. 5 Free energy profiles in chloroform for piperidine attack on the indenyl moiety. The inset shows the optimized geometry of transition state 3b. |
Having reproduced the experimental trends, we performed an analysis of the steric and electronic properties of the various systems to shed light on the structural parameters impacting most of the reactivity behavior. Focusing on steric features, a comparison of the %Vbur and the bite angle results in a strong correlation, R2 = 0.81, for 11 Pd-indenyl complexes (3a–3g of Table 1, bearing two monodentate phosphines, and 4–8 of Table 2, bearing a bidentate phosphine and an indenyl moiety). This indicates that %Vbur and the bite angles can be interchanged as descriptors capturing steric pressure on the active center. As for electronic descriptors, we focused on the charge from natural population analysis (NPA) on the indenyl group, the Pd atom, and the ligand. In addition, we also considered the HOMO and LUMO energies.
Considering the small number of systems, 11, that mono- and bidentate phosphines are intrinsically different in flexibility and that the corresponding complexes contain different counterions, attempts to build a statistically robust regression model failed. We will thus provide qualitative analysis of trends for the 6 and 5 complexes bearing a mono- or bidentate phosphine. The R2 values from univariate linear regression between the single descriptors and the experimental rate constants are reported in Table 3.
Descriptor | Monodentate | Bidentate |
---|---|---|
%VBur | 0.17 | 0.47 |
Bite angle | 0.20 | 0.52 |
E(HOMO) | 0.70 | 0.09 |
E(LUMO) | 0.65 | 0.01 |
E(LUMO) − E(HOMO) | 0.02 | 0.09 |
NPA indenyl | 0.59 | 0.54 |
NPA Pd | 0.38 | 0.49 |
NPA Phosphine | 0.35 | 0.66 |
NPA indenyl-Pd | 0.76 | 0.01 |
NPA ind − (Pd + ligand) | 0.63 | 0.54 |
E diss (indenyl) | 0.67 | 0.95 |
Starting with monodentate systems, poor correlation is observed between the two steric descriptors and the rate constants, with R2 values of approximately 0.2. This poor correlation could either be due to the flexibility of mono-phosphines, impossible to capture with a single geometry, or the fact that four out of the six mono-phosphines differ by the nature of the para substituents. This should minimize differences in steric hindrance while impacting electronic properties. Indeed, a stronger correlation is observed between the rate constants and the HOMO and LUMO energies, as well as the NPA charges, especially of the indenyl ligand, with R2 values of approximately 0.6–0.7. Higher activity corresponds to less electron-rich indenyls, or complexes having lower energy LUMOs, which would be more inclined to undergo nucleophilic attack. Consistently, the LUMO of 3b reported in Fig. 6 is clearly localized on these C atoms. A strong correlation is also achieved using the difference between the indenyl and Pd NPA charges, which can be taken as a measure of the polarization of the Pd-indenyl interaction, with an R2 value of 0.76. Higher rate constants correspond to more polarized Pd-indenyl bonds.
Moving to diphosphine based complexes, a reasonable correlation is observed between the steric descriptors and the rate constants, with R2 values of approximately 0.5. The stronger impact of steric hindrance is in line with the clearly different steric requirements of the four bidentate phosphines, with larger %VBur and bite angles corresponding to higher rate constants. The topographic steric maps in Fig. 7 show how the hindrance in 8 results in a smaller reactive pocket compared to that of 7. A reasonable correlation also results from using NPA charges as electronic descriptors, with R2 values of approximately 0.5. A reasonable correlation is again calculated with the NPA charge on the indenyl moieties, with higher constant rates again corresponding to more electron deficient indenyls.
A comparison between R2 values of the considered mono- and bidentate phosphines seems to indicate that the rate constants of complexes with monodentate phosphines are mostly determined by electronic features, whereas those of complexes with bidentate phosphines are determined by both steric and electronic features. Interestingly, the rate constants of both mono- and bidentate-based complexes correlate well with the indenyl dissociation energies. This can be understood considering that dissociation energies are influenced by both steric and electronic effects, and thus could be considered as a versatile descriptor.
The list of the tested compounds includes only those complexes that have shown no significant decomposition after 24 hours in 1:1 DMSO-d6/D2O solution. Unfortunately, all complexes with para-substituted aryl phosphines 3b–e do not meet this requirement.
To this series of Pd-indenyl compounds we have also added the complex [Pd(DPPE)(η3-allyl)]OTf (9), in order to compare, on equal terms, the behaviours of Pd-indenyl and Pd-allyl fragments.
The cytotoxicity data of our compounds on the three ovarian cancer cell lines are summarised in Table 4, in terms of IC50 values (half inhibitory concentrations). In the same table, data referred to a line of normal cells (MRC-5, human lung fibroblasts) are also reported for comparison. Moreover, all the tests have also been extended to cisplatin as a positive control.
Compound | IC50 (μM) | |||
---|---|---|---|---|
A2780 | A2780cis | OVCAR-5 | MRC-5 | |
Data after 96 h of incubation. Stock solutions in DMSO for all complexes; stock solutions in H2O for cisplatin. A2780, cisplatin-sensitive ovarian cancer cells; A2780cis, cisplatin-resistant ovarian cancer cells; OVCAR-5, high-grade serous ovarian cancer cells; and MRC-5, normal lung fibroblasts. | ||||
Cisplatin | 0.9 ± 0.1 | 32 ± 9 | 1.3 ± 0.1 | 3.48 ± 0.09 |
3a | 0.27 ± 0.02 | 0.26 ± 0.04 | 0.34 ± 0.08 | 2.5 ± 0.4 |
3f | 0.26 ± 0.03 | 0.30 ± 0.04 | 0.48 ± 0.02 | 0.9 ± 0.2 |
3g | 0.13 ± 0.05 | 3.0 ± 0.2 | 4.6 ± 0.5 | 2.27 ± 0.09 |
3h | 0.73 ± 0.07 | 1.2 ± 0.2 | 1.9 ± 0.2 | 3.7 ± 0.3 |
4 | 0.122 ± 0.007 | 0.22 ± 0.07 | 0.10 ± 0.01 | 0.7 ± 0.1 |
5 | 0.12 ± 0.03 | 0.19 ± 0.08 | 0.075 ± 0.002 | 0.51 ± 0.03 |
6 | 0.18 ± 0.02 | 0.17 ± 0.03 | 0.13 ± 0.02 | 0.32 ± 0.03 |
7 | 0.062 ± 0.009 | 0.17 ± 0.05 | 0.15 ± 0.02 | 0.306 ± 0.003 |
8 | 0.29 ± 0.02 | 0.29 ± 0.07 | 0.336 ± 0.008 | 2.4 ± 0.4 |
9 | 0.020 ± 0.004 | 0.051 ± 0.008 | 0.03 ± 0.02 | 0.15 ± 0.06 |
On the basis of the obtained data, the following remarks may be proposed:
(a) All complexes show high antiproliferative activity towards all three types of ovarian cancer cells, with IC50 values always significantly lower than cisplatin (often of about one order of magnitude in the cases of cisplatin sensitive A2780 and OVCAR-5 cell lines). In this respect, we emphasize that OVCAR-5 cells are high-grade serous ovarian cancer (HGSOC) cells, the most common and deadly form of the disease.
(b) With the only exception of the complex coordinating the trifurylphosphine (3g), all assayed Pd-indenyl derivatives exhibit the same degree of toxicity towards cisplatin-sensitive A2780 and cisplatin-resistant A2780cis cell lines. This suggests that our complexes might operate with a mechanism of action different from that of cisplatin (classical DNA metalation). Remarkably, the fact that their IC50 values are lower by about two orders of magnitude than cisplatin qualifies these palladium compounds as potential metallodrugs toward forms of cancer resistant to cisplatin.
(c) The cytotoxicity of all diphosphine Pd-indenyl complexes against tumour cells appears basically independent of the nature of the phosphine used (monodentate or chelate). However, the complex coordinating only one phosphine ([Pd(indenyl)(XPhos)]ClO4 (3h) seems to be slightly less active.
(d) Unfortunately, in most cases our complexes have the same toxicity on tumour and normal cells (MRC-5). The only noteworthy exceptions have been represented by complexes [Pd(indenyl)(PPh3)2]ClO4 (3a) and [Pd(DPEphos)(indenyl)]OTf (8) that show significant selectivity (ca. one order of magnitude) towards cancer cells.
(e) From the comparison between the IC50 values of [Pd(DPPE)(indenyl)]OTf (4) and [Pd(DPPE)(η3-allyl)]OTf (9) it is apparent that the latter complex is more cytotoxic than the former on all tested cell lines. This could make us think that the susceptibility of the polyenyl fragment to undergo nucleophilic attack plays a key role in the mechanism of action of this kind of complex.
These compounds have proven to be ideal for a systematic study of nucleophilic attacks on coordinated-indenyl, an issue that had never been addressed to date. For the case in which the designed nucleophile is an amine, an in-depth kinetic analysis has allowed us to establish the rate law and the consequent reaction mechanism. DFT calculations have confirmed that the rate-determining step of the process is the initial nucleophilic attack of amine on the coordinated indenyl-fragment. This bimolecular step is favoured by the decrease of electron density on the indenyl-fragment and the steric hindrance of ligands. A systematic study, based on experimental data, made it possible to select the most suitable steric and electronic descriptors to predict the susceptibility of the Pd-indenyl complexes to nucleophilic attack. Among steric descriptors, the possibility of using the bite angle of bidentate phosphines should be emphasised, in addition to the most predictable %Vbur.
An interesting and never before attempted application of these new compounds concerns their behaviour in the biological environment. As a matter of fact, a good number of the synthesized Pd-indenyl complexes have shown significant antiproliferative activity towards three different ovarian cancer cell lines. Their cytotoxicity is nearly always significantly higher than cisplatin, used as a positive control. Furthermore, with their effectiveness being basically the same on cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cis) cells, it is reasonable to suppose that these novel complexes present a mechanism of action different from the classical DNA metalation of platinum chemotherapeutics drugs. Complexes 3a and 8 deserve a special mention, coordinating PPh3 and DPEphos respectively that exhibit significant selectivity towards tumor cells.
IR spectra were recorded on a PerkinElmer Spectrum One spectrophotometer and UV-Vis spectra were recorded on a PerkinElmer Lambda 40 spectrophotometer equipped with a PerkinElmer PTP 6 (Peltier temperature programmer) apparatus.
In the case of complex 3a morpholine and diethylamine were also employed as nucleophilic agents.
The kinetic studies of complexes 3a, 3b, 3c, 3e, 3f, 3g, 3h, 5, and 8 were carried out by the UV-Vis technique. A series of preliminary tests were performed in order to evaluate the wavelength of the highest absorbance change. The complex of interest was dissolved in CHCl3 ([complex] = 1 × 10−4–5.0 × 10−5 mol dm−3) in the presence of dimethyl fumarate (3.0 × 10−4–5.0 × 10−5 mol dm−3) and was placed in a thermostated cell compartment at 298 K in a spectrophotometer. An adequate excess of piperidine was added ([piperidine] ≥ 10[complex]) and the reactions were monitored by recording spectra as a function of time at a wavelength interval of 366 to 600 nm. The kinetics of the nucleophile attack was studied by recording spectra with a fixed wavelength for each complex evaluated from 378 to 398 nm under pseudo-first order conditions. To a solution of the complex in 3 mL of CHCl3 ([complex] = 10−4–5.0 × 10−5 mol dm−3) in the presence of dimethyl fumarate (3.0 × 10−4–5.0 × 10−5 mol dm−3), known aliquots of piperidine were added using fresh mother solution in CHCl3 ([piperidine] = 0.06–0.14 mol dm−3) (Fig. S80–S91†).
In the case of complexes 4, 5, and 7 the reactions were too slow for UV-Vis conditions. Therefore, the kinetics of the nucleophilic attack was studied by 1H NMR spectroscopy following the integration change of one characteristic peak related to the initial complex. All spectra were recorded at 298 K in CDCl3 where [complex]0:[dmfu]:[piperidine]0 = 0.01:0.015:0.04 mol dm−3 (Fig. S92–S94†).
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 4.58 (ddd, J = 2.7, 2.0, 0.8 Hz, 1H, H3), 6.38 (d, J = 7.5 Hz, 1H, H4), 6.48–6.54 (m, 1H, H1), 6.71–6.74 (m, 1H, H2), 6.87 (t, J = 7.5 Hz, 1H, H5), 7.07 (t, J = 7.5 Hz, 1H, H6), 7.26 (d, J = 7.5 Hz, 1H, H7), 7.34–7.52 (m, 15H, Ar–H).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 27.5.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 4.63–4.65 (m, 1H, H3), 6.44 (d, J = 7.5 Hz, 1H, H4), 6.54–6.60 (m, 1H, H1), 6.69–6.72 (m, 1H, H2), 6.91 (t, J = 7.5 Hz, 1H, H5), 7.10 (t, J = 7.5 Hz, 1H, H6), 7.28 (d, J = 7.5 Hz, 1H, H7), 7.42–7.31 (m, 12H, Ar–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 80.3 (CH, d, JC–P = 3.8 Hz, C3), 97.7 (CH, d, JC–P = 23.2 Hz, C1), 111.4 (CH, d, JC–P = 5.8 Hz, C2), 116.5 (CH, C4), 120.0 (CH, C7), 126.8 (CH, C5), 127.7 (CH, C6), 129.3 (CH, d, JC–P = 11.5 Hz, Ar–CH), 129.8 (C, d, JC–P = 45.6 Hz, ipso-Ar–C), 134.8 (C, d, JC–P = 1.7 Hz, C3a), 135.1 (CH, d, JC–P = 13.6 Hz, Ar–CH), 135.7 (C, d, JC–P = 4.9 Hz, C7a), 137.9 (C, d, JC–P = 2.6 Hz, p-Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 26.0.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 4.64 (pseudo t, 1H, H3), 6.44 (d, J = 7.5 Hz, 1H, H4), 6.55–6.59 (m, 1H, H1), 6.72–6.76 (m, 1H, H2), 6.92 (t, J = 7.5 Hz, 1H, H5), 7.12 (td, J = 8.6, 1.6 Hz, 7H, H6, Ar–H), 7.30 (d, J = 7.5 Hz, 1H, H7), 7.42–7.50 (m, 6H, Ar–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 79.8 (CH, d, JC–P = 3.7 Hz, C3), 97.3 (CH, d, JC–P = 23.6 Hz, C1), 111.3 (CH, d, JC–P = 5.9 Hz, C2), 116.1 (CH, dd, JC–F, C–P = 21.4, 12.0 Hz, m-Ar–CH), 116.4 (CH, C4), 119.8 (CH, C7), 126.51 (CH, C5), 127.3 (C, dd, JC–P, C–F = 47.6, 3.5 Hz, ipso-Ar–C), 127.4 (CH, C6), 134.7 (C, d, JC–P = 1.5 Hz, C3a), 135.7 (C, d, JC–P = 5.0 Hz, C7a), 135.8 (CH, dd, JC–P, C–F = 14.2, 8.5 Hz, o-Ar–CH), 164.3 (C, dd, JC–F, C–P = 253.5, 2.5 Hz, p-Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 25.3 (q, JP–F = 2.5 Hz).
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −108.0 (d, JF–P = 2.5 Hz).
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 4.71 (pseudo t, 1H, H3), 6.39 (d, J = 7.4 Hz, 1H, H4), 6.60–6.67 (m, 1H, H1), 6.72 (pseudo t, 1H, H2), 6.92 (t, J = 7.5 Hz, 1H, H5), 7.14 (t, J = 7.5 Hz, 1H, H6), 7.31 (d, J = 7.4 Hz, 1H, H7), 7.54–7.76 (m, 12H, Ar–H).
13C{1H} NMR (100.0 MHz, CDCl3, T = 298 K, ppm) δ: 80.9 (CH, d, JC–P = 3.6 Hz, C3), 98.2 (CH, d, JC–P = 23.1 Hz, C1), 111.6 (CH, d, JC–P = 5.9 Hz, C2), 116.5 (CH, C4), 120.2 (CH, C7), 123.5 (C, d, JC–F = 272.8 Hz, CF3–C), 125.8–126.0 (CH, o,m-Ar–CH), 127.2 (CH, C5), 128.1 (CH, C6), 133.4 (C, dd, JC–P, C–F = 32.9, 2.6 Hz, p-Ar–C), 134.3–134.6 (CH, o,m-Ar–CH), 134.8 (C, JC–P = 1.5 Hz, C3a), 135.2 (C, d, JC–F = 42.5 Hz, ipso-Ar–C), 135.6 (C, d, JC–P = 5.0 Hz, C7a).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 28.0.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −63.2.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 3.82 (s, 9H, OCH3) 4.57 (pseudo t, 1H, H3), 6.46 (d, J = 7.8 Hz, 2H, H1, H4), 6.72 (pseudo t, 1H, H2), 6.89 (d, J = 8.7 Hz, 7H, H5, Ar–H), 7.07 (t, J = 7.5 Hz, 1H, H6), 7.25 (d, J = 7.8 Hz, 1H, H7), 7.38 (dd, J = 11.3, 8.7 Hz, 6H, Ar–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 55.5 (CH3, OCH3), 78.9 (CH, d, JC–P = 3.9 Hz, C3), 96.9 (CH, d, JC–P = 23.2 Hz, C1), 111.2 (CH, d, JC–P = 5.9 Hz, C2), 114.2 (CH, d, JC–P = 11.9 Hz, o-Ar–CH), 116.8 (CH, C4), 119.6 (CH, C7), 123.7 (C, d, JC–P = 50.9 Hz, ipso-Ar–C), 126.1 (CH, C5), 127.0 (CH, C6), 135.1 (C, d, JC–P = 1.9 Hz, C3a), 135.5 (CH, d, JC–P = 13.7 Hz, m-Ar–CH), 136.2 (C, d, JC–P = 4.7 Hz, C7a), 161.5 (C, d, JC–P = 2.4 Hz, p-Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 23.5.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 4.82 (pseudo t, 1H, H3), 6.39 (d, J = 7.5 Hz, 1H, H4), 6.52–6.58 (m, 1H, H1), 6.67–6.70 (m, 1H, H2), 6.84 (t, J = 7.5 Hz, 1H, H5), 7.06 (t, J = 7.5 Hz, 1H, H6), 7.25 (d, J = 7.5 Hz, 1H, H7) 7.28–7.74 (m, 13H, Ar–H, Py–H), 7.79 (d, J = 4.2 Hz, 1H, 6-Py–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm, selected peaks) δ: 78.5 (CH, C3), 97.7 (CH, d, JC–P = 23.0 Hz, C1), 111.4 (CH, d, JC–P = 5.9 Hz, C2), 116.9 (CH, C4), 119.6 (CH, C7), 124.3 (CH, d, JC–P = 2.4 Hz, 3-Py–C), 126.4 (CH, C5), 127.2 (CH, C6), 128.5 (CH, d, JC–P = 10.8 Hz, Ar–CH), 128.6 (CH, d, JC–P = 10.8 Hz, Ar–CH), 130.8–131.5 (C, CH, Ar–C, Py–CH), 132.1 (C, C3a) 134.2 (CH, d, JC–P = 12.1 Hz, Ar–CH), 134.5 (CH, d, JC–P = 12.1 Hz, Ar–CH), 134.9 (C, C7a) 136.0 (CH, d, JC–P = 4.6 Hz, Py–CH), 136.1 (CH, d, JC–P = 9.5 Hz, Py–CH), 150.4 (CH, d, JC–P = 14.6 Hz, 6-Py), 156.8 (C, d, JC–P = 65.4 Hz, 2-Py).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 29.3.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 5.52 (pseudo t, 1H, H3), 6.49–6.44 (m, 3H, Furyl–H), 6.64 (bd, 1H, H1), 6.73–6.68 (m, 2H, H2, H4), 6.91 (t, J = 7.5 Hz, 1H, H5), 6.97 (t, J = 2.9 Hz, 3H, Furyl–H), 7.07 (t, J = 7.5 Hz, 1H, H6), 7.25 (d, J = 6.5 Hz, 1H, H7), 7.71 (s, 3H, Furyl–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 76.2 (CH, d, JC–P = 3.6 Hz, C3), 98.9 (CH, d, JC–P = 25.3 Hz, C1), 111.4 (CH, d, JC–P = 5.7 Hz, C2), 111.6 (CH, d, JC–P = 8.7 Hz, Furyl–CH), 118.3 (CH, C4), 119.8 (CH, C7), 124.7 (CH, d, JC–P = 23.3 Hz, Furyl–CH), 126.8 (CH, C5), 127.8 (CH, C6), 135.2 (C, d, JC–P = 1.5 Hz, C3a), 136.3 (C, d, JC–P = 5.5 Hz, C7a), 143.5 (C, d, JC–P = 71.9 Hz, Furyl–C) 148.7 (CH, d, JC–P = 5.3 Hz, Furyl–CH).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: −28.5.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 0.94 (d, J = 6.7 Hz, 6H, iPr–CH3–H), 1.01 (d, J = 6.7 Hz, 6H, iPr–CH3–H), 0.86–1.12 (m, 2H, Cy–CH–H), 1.28 (dt, J = 7.0, 4.2 Hz, 6H, iPr–CH3–H), 1.23–1.50 (br, 16H, Cy–CH2–H), 1.58 (br, 4H, Cy–CH2–H), 2.46 (p, J = 6.8 Hz, 1H, iPr–CH–H), 2.66 (p, J = 6.8 Hz, 1H, iPr–CH–H), 2.93 (p, J = 6.8 Hz, 1H, iPr–CH–H), 4.98 (bs, 1H, H3), 6.22–6.27 (m, 1H, H1), 6.59–6.63 (m, 1H, H2), 6.83 (d, J = 7.4 Hz, H4), 6.91 (t, J = 7.4 Hz, H5), 6.95–7.10 (m, 4H, H6, Ar–H), 7.20 (d, J = 7.4 Hz, 1H, H7), 7.34–7.39 (m, 2H, Ar–H), 7.79–7.89 (m, 1H, Ar–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 22.4–28.2 (CH3, CH2, CH, iPr–CH3, Cy–CH2, Cy–CH), 30.9 (CH, iPr–CH), 31.0 (CH, iPr–CH), 34.6 (CH, iPr–CH), 73.3 (CH, d, JC–P = 3.7 Hz, C3), 94.8 (CH, d, JC–P = 22.5 Hz, C1), 111.5 (CH, d, JC–P = 6.0 Hz, C2), 117.2 (CH, C4), 119.5 (CH, C7), 121.2 (CH, d, JC–P = 3.9 Hz, Ar–CH), 125.3 (CH, C5), 126.0 (CH, JC–P = 13.8 Hz, Ar–CH), 126.8 (CH, C6), 128.5 (CH, d, JC–P = 2.4 Hz, Ar–CH), 132.3 (C, d, JC–P = 27.1 Hz, ipso-Ar–C), 133.8 (CH, d, JC–P = 6.4 Hz, Ar–CH), 136.4 (C, d, JC–P = 1.5 Hz, C3a), 136.5–136.6 (C, Ar–C), 137.4 (C, d, JC–P = 4.7 Hz, C7a), 137.6–138.1 (CH, Ar–CH), 141.4 (C, Ar–C), 146.4 (C, d, JC–P = 7.3 Hz, Ar–C), 149.2 (C, Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 57.9.
All neutral complexes [PdCl(indenyl)(PAr3)] isolated contain always small traces of the respective Pd(I) dimers [(μ-η3-ind)(μ-Cl)Pd2(PAr3)2], and for this reason the elemental analyses were not helpful for their characterization.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 5.48–5.51 (m, 2H, H1, H3), 6.18–6.28 (m, 2H, H4, H7), 7.06–7.12 (m, 14H, H5, H6, Ar–H), 7.30 (t, J = 7.3 Hz, 13H, H2, Ar–H), 7.21 (t, J = 7.4 Hz, 6H, p-Ar–H).
13C{1H} NMR (100.0 MHz, CDCl3, T = 298 K, ppm) δ: 95.6 (CH, t, JC–P = 11.7 Hz, C1, C3), 114.0 (CH, t, JC–P = 5.3 Hz C2), 118.9 (CH, C4, C7), 127.9 (CH, C5, C6), 129.1 (CH, t, JC–P = 5.8 Hz, Ar–CH), 130.2 (C, dd, JC–P = 24.0, 23.1 Hz, ipso-Ar–C), 131.4 (CH, p-Ar–CH), 132.0 (C, t, JC–P = 3.2 Hz, C3a, C7a), 133.6 (CH, t, JC–P = 6.1 Hz, Ar–CH).
31P{1H} NMR (162.0 MHz, CDCl3, T = 298 K, ppm) δ: 26.4.
IR (KBr pellet, cm−1): νClO = 1091, δClO = 623.
Elemental analysis calcd (%) for C45H37ClO4P2Pd: C, 63.92, H, 4.41; found: C, 63.64, H, 4.58.
HRMS calcd for [C45H37P2Pd]+: 745.1405; found: 745.1440.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 5.50–5.53 (m, 2H, H1, H3), 6.47–6.49 (m, 2H, H4, H7), 7.03–7.09 (m, 12H, o-Ar–H), 7.14–7.17 (m, 2H, H5, H6), 7.33 (d, J = 8.0 Hz, 12H, m-Ar–H), 7.56 (t, J = 3.3 Hz, H2).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 97.0 (CH, t, JC–P = 11.7 Hz, C1, C3), 116.2 (CH, t, JC–P = 5.6 Hz C2), 118.9 (CH, C4, C7), 128.0 (C, dd, JC–P = 23.8, 23.7 Hz, ipso-Ar–C), 128.2 (CH, C5, C6), 129.7 (CH, t, JC–P = 5.8 Hz, m-Ar–CH), 132.3 (C, C3a, C7a), 134.7 (CH, t, JC–P = 6.7 Hz, o-Ar–CH), 138.8 (C, p-Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 24.4.
IR (KBr pellet, cm−1): νClO = 1089, δClO = 622.
Elemental analysis calcd (%) for C45H31Cl7O4P2Pd: C, 51.37, H, 2.97; found: C, 51.69, H, 2.80.
HRMS calcd for [C45H31Cl6P2Pd]+: 952.9042; found: 952.9018.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 5.49–5.53 (m, 2H, H1, H3), 6.41–6.44 (m, 2H, H4, H7), 7.00–7.21 (m, 26H, H5, H6, Ar–H) 7.54 (t, J = 3.3 Hz, H2).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 96.4 (CH, t, JC–P = 11.9 Hz, C1, C3), 116.0 (CH, d, JC–P = 4.6 Hz C2), 116.8 (CH, td, JC–F, C–P = 21.6, 6.2 Hz, m-Ar–CH), 118.9 (CH, C4, C7), 125.9 (C, dd, JC–P, C–P, C–F = 26.4, 24.0, 3.4 Hz, ipso-Ar–C), 128.0 (CH, C5, C6), 132.3 (C, t, JC–P = 3.2 Hz, C3a, C7a), 135.8 (CH, dt, JC–P = 7.6 Hz, JC–F = 7.6 Hz, o-Ar–CH), 164.6 (C, d, JC–F = 255.8 Hz, p-Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 24.0.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −106.0
IR (KBr pellet, cm−1): νClO = 1091, δClO = 623.
Elemental analysis calcd (%) for C45H31ClF6O4P2Pd: C, 56.68, H, 3.28; found: C, 57.01, H, 3.10.
HRMS calcd for [C45H31F6P2Pd]+: 853.0840; found: 853.0895.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 3.83 (s, 18H, o-CH3–H), 5.37–5.41 (m, 2H, H1, H3), 6.41–6.44 (m, 2H, H4, H7), 6.80 (d, J = 8.1 Hz, 12H, Ar–H), 6.90–7.00 (m, 12H, Ar–H), 7.11–7.15 (m, 3H, H2, H5, H6).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm) δ: 55.7 (CH, OCH3), 94.5 (CH, t, JC–P = 12.0 Hz, C1, C3), 113.3 (CH, C2), 114.5 (CH, t, JC–P = 6.0 Hz, o, m-Ar–CH), 118.9 (CH, C4, C7), 122.0 (C, dd, JC–P = 26.7, 26.4 Hz, ipso-Ar–C), 127.4 (CH, C5, C6), 132.0 (C, t, JC–P = 3.1 Hz, C3a, C7a), 135.1 (CH, t, JC–P = 6.9 Hz, o, m-Ar–CH), 161.8 (C, p-Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 23.1.
IR (KBr pellet, cm−1): νClO = 1090, δClO = 623.
Elemental analysis calcd (%) for C45H49ClO10P2Pd: C, 59.72, H, 4.82; found: C, 59.38, H, 5.04.
HRMS calcd for [C51H49O6P2Pd]+: 925.2039; found: 925.2135.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm) δ: 5.57–6.62 (m, 2H, H1, H3), 6.19–6.22 (m, 2H, H4, H7), 6.87–6.98 (m, 3H, H2, Py–H), 7.01–7.05 (m, 2H, H5, H6), 7.07–7.54 (m, 24H, Ar–H, Py–H,), 8.25 (d, J = 4.4 Hz, 2H, 6-Py–H).
13C{1H} NMR (100.0 MHz, CDCl3, T = 298 K, ppm) δ: 94.6 (CH, t, JC–P = 11.6 Hz, C1, C3), 112.0 (CH, t, JC–P = 5.2 Hz C2), 118.7 (CH, C4, C7), 124.7 (CH, Py–CH), 128.0 (CH, C5, C6), 128.1–136.7 (CH, C, Ar–CH, Ar–C, Py–CH, Py–C), 131.1 (C, t, JC–P = 3.2 Hz, C3a, C7a), 150.2 (CH, t, JC–P = 9.0 Hz, 6-Py–CH), 154.7–156.3 (CH, C, Ar–CH, Ar–C, Py–CH, Py–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 27.5.
IR (KBr pellet, cm−1): νClO = 1093, δClO = 620.
Elemental analysis calcd (%) for C43H35ClN2O4P2Pd: C, 60.93, H, 4.16, N, 3.31; found: C, 60.65, H, 4.32, N, 3.57.
HRMS calcd for [C43H32N2P2Pd]+: 747.1310; found: 747.1315.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 6.47 (dd, J = 3.5, 1.7 Hz, 6H, Furyl–H), 6.50–6.58 (m, 8H, H1, H3, Furyl–H), 6.73–6.81 (m, 2H, H4, H7), 6.83 (t, J = 3.2 Hz, 1H, H2), 7.15–7.17 (m, 2H, H5, H6), 7.61–7.63 (m, 6H, Furyl–H).
13C{1H} NMR (100 MHz, CDCl3, T = 298 K, ppm) δ: 93.9 (CH, t, JC–P = 12.1 Hz, C1, C3), 111.1 (CH, t, JC–P = 6.3 Hz, C2), 112.1 (CH, t, JC–P = 4.0 Hz, Furyl–C), 120.1 (CH, C4, C7), 124.2 (CH, t, JC–P = 9.7 Hz, Furyl–C), 128.6 (CH, C5, C6), 131.1 (C, t, JC–P = 3.7 Hz, C3a, C7a), 140.9–142.6 (C, Furyl–C), 149.5 (CH, t, JC–P = 3.2 Hz, Furyl–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: −27.1.
IR (KBr pellet, cm−1): νClO = 1108, δClO = 622.
Elemental analysis calcd (%) for C33H25ClO10P2Pd: C, 50.47, H, 3.21; found: C, 50.80, H, 3.01.
HRMS calcd for [C33H25O6P2Pd]+: 685.0161; found: 685.0206.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 0.55 (d, J = 6.7 Hz, 3H, iPr–CH3), 0.76 (d, J = 6.7 Hz, 3H, iPr–CH3), 0.86 (d, J = 6.7 Hz, 3H, iPr–CH3), 1.13–1.45 (m, 8H, Cy–CH2), 1.46–1.50 (m, 8H, iPr–CH3, Cy–CH2), 1.54 (d, J = 6.9 Hz, 3H, iPr–CH3), 1.65–1.98 (m, 8H, Cy–CH2), 2.08 (p, J = 6.7 Hz, 1H, iPr–CH), 2.11–2.25 (m, 3H, iPr–CH, Cy–CH2), 2.33–2.42 (m, 1H, Cy–CH), 2.48–2.57 (m, 1H, Cy–CH), 3.18 (p, J = 6.9 Hz, 1H, iPr–CH), 4.58–4.63 (m, 1H, H3), 6.23–6.24 (m, 1H, H1), 6.62–6.64 (m, 1H, H2), 6.69 (dd, J = 7.3, 2.7, Hz, 1H, Ar–H), 6.83 (d, J = 7.5 Hz, 1H, H7), 6.96 (t, J = 7.5 Hz, 1H, H5), 7.08 (t, J = 7.5 Hz, 1H, H6), 7.20 (s, 1H, Ar–H), 7.28 (d, J = 7.5 Hz, 1H, H4), 7.44 (tt, J = 7.5, 1.7 Hz, 1H, Ar–H), 7.50 (s, 1H, Ar–H), 7.53 (tt, J = 7.5, 1.7 Hz, 1H, Ar–H), 7.70 (t, J = 7.1 Hz, 1H, Ar–H).
13C{1H} NMR (100.0 MHz, CDCl3, T = 298 K, ppm) δ: 23.6–25.9 (CH, iPr–CH3), 26.0–30.2 (CH2, Cy–CH2), 32.0–34.3 (CH, iPr–CH), 37.3 (CH, d, JC–P = 18.9 Hz, CH–Cy), 37.6 (CH, d, JC–P = 21.4 Hz, CH–Cy), 71.1 (CH, d, JC–P = 3.3 Hz, C3), 113.8 (CH, d, JC–P = 6.9 Hz, C2), 116.9 (CH, d, JC–P = 21.4 Hz, C1), 118.3 (C, d, JC–P = 4.4 Hz, Ar–C), 119.4 (CH, C7), 121.0 (CH, C4), 125.8 (CH, Ar–CH), 126.4 (CH, Ar–CH), 127.6 (CH, C5), 128.9 (CH, d, JC–P = 5.5 Hz, Ar–CH), 129.3 (CH, C6), 131.8–132.4 (CH, Ar–CH), 132.9 (C, d, JC–P = 38.9 Hz, Ar–C), 134.8 (C, d, JC–P = 2.2 Hz, C3a), 138.8 (C, d, JC–P = 5.1 Hz, C7a), 145.1 (C, d, JC–P = 20.3 Hz, Ar–C), 146.0 (C, Ar–C), 150.3 (C, Ar–C), 152.3 (C, Ar–C).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 54.9.
IR (KBr pellet, cm−1): νClO = 1089, δClO = 623.
Elemental analysis calcd (%) for C42H56ClO4PPd: C, 63.24, H, 7.08; found: C, 62.87, H, 7.26.
HRMS calcd for [C42H56PPd]+: 697.3154; found: 697.3209.
1H NMR (300 MHz, CDCl3, T = 298 K, ppm,) δ: 2.50 (d, J = 19.1 Hz, 4H, PCH2), 6.33 (pseudo q, 2H, H1, H3), 6.60 (t, J = 3.2 Hz, 1H, H2), 6.63–6.70 (m, 2H, H4, H7), 7.03–7.11 (m, 2H, H5, H6), 6.80–7.80 (bm, 20H, Ar–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm, selected peaks) δ: 28.0 (CH2, t, JC–P = 24.3 Hz, PCH2), 88.4 (CH, t, JC–P = 11.9 Hz, C1, C3), 109.5 (CH, bt, C2), 118.9 (CH, C4, C7), 127.1 (CH, C5, C6), 128.9 (C, C3a, C7a).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 61.0.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −78.1.
IR (KBr pellet, cm−1): νCF = 1230, νSO = 1026, δSO = 633.
Elemental analysis calcd (%) for C36H31F3O3P2PdS: C, 56.22, H, 4.06, S, 4.17; found: C, 56.60, H, 3.91, S, 4.34.
HRMS calcd for [C42H56P2Pd]+: 619.0936; found: 619.0972.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 1.50–3.00 (bm, 6H, CH2), 5.29 (pseudo q, 2H, H1, H3), 6.81 (t, J = 3.1 Hz, 1H, H2), 6.82–6.86 (m, 2H, H4, H7), 6.94 (bs, 4H, Ar–H), 7.13–7.19 (m, 2H, H5, H6), 7.33–7.60 (bm, 16H, Ar–H).
13C{1H} NMR (75.0 MHz, CDCl3, T = 298 K, ppm, selected peaks) δ: 18.5 (CH2, CH2), 24.6 (CH2, t, JC–P = 17.5 Hz, PCH2), 92.5 (CH, t, JC–P = 12.0 Hz, C1, C3), 111.6 (CH, t, JC–P = 5.8 Hz, C2), 118.5 (CH, C4, C7), 126.5 (CH, C5, C6), 129.2 (CH, bs, Ar–CH), 129.8 (C, t, JC–P = 5.8 Hz, C3a, C7a).
31P{1H} NMR (162.0 MHz, CDCl3, T = 298 K, ppm) δ: 8.2.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −78.0.
IR (KBr pellet, cm−1): νCF = 1221, νSO = 1152, δSO = 635, 512.
Elemental analysis calcd (%) for C37H33F3O3P2PdS: C, 56.75, H, 4.25, S, 4.09; found: C, 56.40, H, 4.43, S, 4.48.
HRMS calcd for [C36H33P2Pd]+: 633.1092; found: 633.1133.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 4.03 (s, 2H, Fc–H), 4.22 (s, 2H, Fc–H), 4.43 (d, J = 15.8 Hz, 4H, Fc–H), 5.45 (pseudo q, 2H, H1, H3), 6.16–6.22 (m, 2H, H4, H7), 6.95 (t, J = 3.1 Hz, 1H, H2), 7.00–7.05 (m, 2H, H5, H6), 7.15–7.26 (m, 4H, Ar–H), 7.52 (t, J = 7.5 Hz, 4H, p-Ar–H), 7.58–7.68 (m, 12H, Ar–H).
13C{1H} NMR (100.0 MHz, CDCl3, T = 298 K, ppm) δ: 72.5 (C, dd, JC–P = 31.4, 30.2 Hz, Fc–C), 74.2 (CH, t, JC–P = 3.9 Hz, Fc–CH), 74.4 (CH, t, JC–P = 3.7 Hz, Fc–CH), 76.1 (CH, dt, JC–P = 12.0, 5.8 Hz, Fc–CH), 94.2 (CH, t, JC–P = 11.8 Hz, C1, C3), 112.5 (CH, t, JC–P = 5.4 Hz, C2), 118.5 (CH, C4, C7), 127.9 (CH, C5, C6), 129.2 (CH, t, JC–P = 5.5 Hz, Ar–CH), 129.7 (CH, t, JC–P = 5.5 Hz, Ar–CH), 130.5 (C, t, JC–P = 3.1 Hz, C3a, C7a), 131.6 (C, Ar–C), 132.4–133.5 (CH, Ar–CH), 134.1 (CH, JC–P = 6.6 Hz, Ar–CH).
31P{1H} NMR (162.0 MHz, CDCl3, T = 298 K, ppm) δ: 30.1.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −77.9.
IR (KBr pellet, cm−1): νSO = 1312, νCF = 1224, 1160, νSO = 1031, δSO = 637.
Elemental analysis calcd (%) for C44H35F3FeO3P2PdS: C, 57.13, H, 3.81, S, 3.47; found: C, 56.84, H, 3.98, S, 3.80.
HRMS calcd for [C43H35FeP2Pd]+: 775.0598; found: 775.0649.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 6.30 (pseudo q, 2H, H1, H3), 6.48–6.54 (m, 2H, H4, H7), 6.66 (t, J = 3.2 Hz, 1H, H2), 6.89–6.96 (m, 2H, H5, H6), 6.80–7.68 (bm, 24H, Ar–H).
13C{1H}-NMR (100.0 MHz, CDCl3, T = 298 K, ppm, selected peaks) δ: 89.6 (CH, t, JC–P = 11.9 Hz, C1, C3), 110.0 (bt, C2), 118.6 (CH, C4, C7), 127.3 (CH, C5, C6), 128.6 (C, t, JC–P = 3.1 Hz, C3a, C7a).
31P{1H} NMR (162.0 MHz, CDCl3, T = 298 K, ppm) δ: 57.7.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −78.0.
IR (KBr pellet, cm−1): νSO = 1313, νCF = 1223, 1149, νSO = 1030, δSO = 636.
Elemental analysis calcd (%) for C40H31F3O3P2PdS: C, 58.80, H, 3.82, S, 3.92; found: C, 58.54, H, 3.99, S, 3.78.
HRMS calcd for [C39H31P2Pd]+: 667.0936; found: 667.0989.
1H NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 5.59 (pseudo q, 2H, H1, H3), 5.72–5.79 (m, 2H, H4, H7), 6.64 (q, J = 6.8 Hz, 4H, Ar–H), 6.86–7.02 (m, 9H, H2, H5, H6, Ar–H), 7.27–7.64 (m, 18H, Ar–H).
13C{1H} NMR (100.0 MHz, CDCl3, T = 298 K, seleckted peaks, ppm) δ: 95.0 (CH, C1, C3), 112.6 (CH, t, JC–P = 5.6 Hz, C2), 118.5 (CH, C4, C7), 128.0 (CH, C5, C6), 131.5 (C, C3a, C7a).
31P{1H} NMR (121.5 MHz, CDCl3, T = 298 K, ppm) δ: 15.8.
19F{1H} NMR (377.2 MHz, CDCl3, T = 298 K, ppm) δ: −77.9.
IR (KBr pellet, cm−1): νCF = 1222, 1146, νSO = 1031, δSO = 636.
Elemental analysis calcd (%) for C46H35F3O4P2PdS: C, 60.77, H, 3.88, S, 3.53; found: C, 61.03, H, 3.70, S, 3.39.
HRMS calcd for [C45H35OP2Pd]+: 759.1198; found: 759.1264.
Footnote |
† Electronic supplementary information (ESI) available. CCDC 2173701–2173705. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d2dt01821g |
This journal is © The Royal Society of Chemistry 2022 |